DaVita (NYSE:DVA) Stock Rating Lowered by StockNews.com

DaVita (NYSE:DVA) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday.

Other equities research analysts have also recently issued reports about the company. Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on DaVita in a report on Friday, February 21st. Finally, Barclays lifted their target price on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $166.33.

DaVita Price Performance

Shares of DVA traded down $0.76 during mid-day trading on Friday, reaching $148.25. The company had a trading volume of 1,036,193 shares, compared to its average volume of 783,765. DaVita has a twelve month low of $125.64 and a twelve month high of $179.60. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The company’s 50-day moving average is $158.53 and its 200-day moving average is $157.48. The company has a market capitalization of $11.86 billion, a P/E ratio of 13.80, a P/E/G ratio of 1.07 and a beta of 0.99.

DaVita (NYSE:DVA) last released its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, equities analysts anticipate that DaVita will post 10.76 EPS for the current year.

Institutional Trading of DaVita

A number of hedge funds and other institutional investors have recently modified their holdings of DVA. United Capital Financial Advisors LLC lifted its stake in DaVita by 2.6% during the fourth quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company’s stock worth $361,000 after purchasing an additional 62 shares during the last quarter. Freedom Investment Management Inc. increased its holdings in shares of DaVita by 3.6% during the fourth quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company’s stock worth $268,000 after buying an additional 62 shares in the last quarter. MML Investors Services LLC increased its holdings in shares of DaVita by 1.3% during the third quarter. MML Investors Services LLC now owns 5,300 shares of the company’s stock worth $869,000 after buying an additional 68 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of DaVita by 8.3% during the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company’s stock worth $133,000 after buying an additional 68 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in shares of DaVita by 2.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the company’s stock worth $531,000 after buying an additional 69 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.